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Abstract—The aim of this study is to reveal the discriminative 
potential of energy related metabolites in brain gliomas 
classification. The proposed analysis considers two aspects, the 
statistical and biological verification of metabolites’ effects. In 
particular, Magnetic Resonance Spectroscopic Imaging (MRSI) 
is first employed for the statistical evaluation of metabolites. Five 
of the identified significant metabolites, namely glucose, 
pyruvate, lactate, alanine and lipids, are involved in the energy 
production process, necessary for the survival of the cell.   In the 
second stage of analysis, we consider specific metabolic pathways 
like glycolysis, lactate fermentation, citric acid cycle and 
lipogenesis in order to evaluate the role of these metabolites in 
the energy production process.  
The results of the proposed double process have shown that 
these five metabolites are capable to discriminate the three types 
of gliomas provided. Low grade glioma (GR2) can be 
discriminated from intermediate grade ones (GR3) with accuracy 
of 86%. Intermediate grade gliomas versus high grade ones 
(GR4) with accuracy of 98% and finally low grade versus high 
grade with accuracy of 100%. Accuracy was extensively 
evaluated with the area under the ROC (AUROC) global metric.  
Keywords-Energy metabolism; brain gliomas; magnetic 
resonance spectroscopy 
I.        INTRODUCTION 
Energy production is a vital metabolic function of a human 
cell. Under normal conditions the human brain cells acquire 
their energy through predefined metabolic pathway called 
glycolysis. Glycolysis (a sugar splitting process), as shown in 
Fig. 1, involves a series of biochemical reactions in which 
glucose is broken down to pyruvate with the release of usable 
energy in the form of ATP (adenosine triphosphate) 
molecules. Under aerobic conditions (aerobic glycolysis), the 
brain derives almost all of its energy from the aerobic oxidation 
of glucose [1-3]. Pyruvate metabolite which is the end product of 
this process enters the mitochondria of neurons and glia and the 
citric acid cycle, also called TCA cycle begins were 36 ATP 
molecules of energy are finally produced. Only about 13% of 
glycolytic pyruvate is converted to lactate under normal 
conditions [3]. 
In contrast to normal brain cells the malignant rapidly-
growing glioma cells present very high glycolytic rates [4]. There 
are two common reasons for this fact. The classical explanation 
is that there is poor blood supply to tumors causing local 
depletion of oxygen. The other explanation stems from the 
well known hypothesis of Otto Warburg, who claimed that 
most cancer cells predominantly produce energy by glycolysis 
followed by lactic acid (lactate) fermentation in the cytosol, 
rather than by oxidation of pyruvate in mitochondria like most 
normal cells [5]. This occurs even if oxygen is plentiful. 
Warburg postulated that this change in metabolism is the 
fundamental cause of cancer [6], a claim now known as the 
Warburg effect. This effect may simply be a consequence of 
damage to the mitochondria in cancer cells, or an adaptation to 
low-oxygen environments within tumors, or a result of cancer 
genes shutting down the mitochondria because they are 
involved in the cell's apoptosis program, which would 
otherwise kill cancerous cells.  
The Warburg effect may also be associated with cell 
proliferation. Since glycolysis provides most of the building 
blocks required for cell proliferation, it has been proposed that 
cancer cells (and normal proliferating cells) may need to 
activate glycolysis despite the presence of oxygen in order to 
proliferate [7].  
When oxygen is depleted, as for instance in hypoxic-
necrotic tumorous tissues of gliomas, the dominant glycolytic 
product in many tissues is lactate and the process is known as 
anaerobic glycolysis. 
Thus, lactate metabolite is a sensitive indicator of 
anaerobic glycolysis and reduced cellular oxygenation in 
living tissues. Along similar lines, alanine, in conjunction with 
lactate, increases in tissues during hypoxia; made by 
transamination of pyruvate to prevent further increases in 
lactate [8]. 
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Figure 1. The energy production process in a human cell 
Furthermore, lipids and fatty acid syntheses are increased 
in gliomas [9]. 
Therefore, reliable estimates of the levels of glucose, 
pyruvate, lactate, alanine and lipid substrates are of special 
interest for the clinical management of brain gliomas patients.  
The main goal of this study is to reveal the significance of 
these metabolites in the discrimination of different glioma 
types, thus providing a way to further improve the diagnostic 
accuracy in today’s clinical practices. This is done through a 
double process that evaluates the significance of metabolites 
in both a statistical and a biological perspective. The statistical 
evaluation involves the derivation of significant metabolites 
from a dataset of MRSI exams. Besides, the biological 
framework of evaluation involves verification of the results 
through existing studies, as to enhance their validity and 
importance. 
II.        MATERIALS AND METHODS 
 The metabolic pathways that compose the energy 
production process are included in the well known Human 
Metabolome Database (HMDB) and the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) available in the internet. A 
thorough examination of the biochemical properties of 
glucose, pyruvate, lactate, alanine and lipids showed that these 
metabolites are vital for the energy production, as described in 
the Introduction section above.  
TABLE I.  ANALYSIS OF THE DATASET 
Tissue type No of subjects No of voxels 
GR2 10 176 
GR3 4 57 
GR4 7 70 
Total 21 303 
GR2: glioma grade 2, GR3: glioma grade 3 and GR4: glioma grade 4 
In order then to identify the significance of these 
metabolites in the discrimination of different types of gliomas, 
we estimated their peak area levels in a real dataset which 
consists of short echo magnetic resonance spectroscopy 
imaging (MRSI) data from 21 glioma patients, as presented in 
Table I. 
The two-dimensional MRSI data was collected by the 
Radboud University and contains 303 pre-processed proton-
MRSI (1H-MRSI) volume elements (voxels) corresponding to 
303 spectra. Each patient case had passed strict quality control 
and validation procedures, including consensus 
histopathologic determination. 
The peak areas, Fig. 2, were obtained by peak integration 
[10, 11] of glucose (at 3.44 ppm), pyruvate (at 2.37 ppm), 
alanine (at 1.48 ppm), lactate (at 1.33 ppm) and lipids (the 
sum of the resonances at 0.90 and 1.30 ppm). 
The discriminative potential of these five metabolites was 
evaluated through the 3 different binary classification schemes 
(GR2 vs GR3, GR3 vs GR4 and GR2 vs GR4), using Support 
Vector Machines (SVMs) classifier [12] with a Radial Basis 
Function (RBF) kernel. Kernel-based methods can perform 
well in processing when high dimensional and heterogeneous 
data are under scrutiny. The parameters of RBF kernels (C, γ) 
were tuned in each binary classification in such a way that the 
smallest possible number of support vectors would be retained 
for training purposes, as to avoid overtraining.  
The SVM solution is based only on those data samples that 
are at the margin of the decision boundary, called support 
vectors (lie on the dashed lines in Fig. 3). In essence, SVM 
attempts to find the best separating hyperplane to distinguish 
between the two classes of interest, positive (+1) and negative 
(−1). This is done by maximizing the distance w/2  
between the two parallel lines 1)( =+× bxw  and 
1)( −=+× bxw , which form the margin of separation of 
the two classes as shown in Fig. 3. 
 
The separating hyperplane passes through the middle of this 
margin with equation 0)( =+× bxw . The decision 
function, (1) then, is a function of the form: 
 
 ))sgn(()( bxwxf +⋅=  (1) 
 
where w represents the direction vector of the hyperplane. The 
sign of the value returned by (1) indicates the predicted class 
associated with example x, while | f (x)| indicates the 
confidence level of the resulting decision. 
 
 
 
 
 
Figure 2. Spectrum obtained from a voxel. Y axis: peak heights (proportional 
to metabolites concentration). X axis: frequency (position) in parts per 
million. Gluc (Glucose), Pyr (Pyruvate), Ala (Alanine), Lac (Lactate), Lipids 
(mobile lipids) are the metabolites observed. The shaded area is just for 
presentation purposes, not the real measured areas under the peaks. 
Figure 3.  The SVM solution based on the separating hyperplane 
 
The evaluation of classifier performance was assessed 
through a 10-fold Cross Validation (CV) method and the 
classification accuracy was measured in terms of AUROC 
values. In 10-fold CV, 100 stratified random splits of the 
initial dataset containing 303 voxels were created. For each 
binary classification scheme the train sets contained 90% of 
the voxels of each of the two classes and the remaining 10% 
of these two classes were contained in the test sets. 
The statistical significance of the selected metabolites was 
also measured through Independent-Samples t-test. The values 
of the means of each one of the five metabolites were 
estimated in each class and the p-values were computed. A 
mean’s difference was considered significant (S) when its p-
value was less than 0.05, highly significant (HS) for less that 
0.001 and non-significant (NS) when greater than 0.05.  
The software package used for the construction of SVM 
classifier was Matlab ver. 7.9 and for the statistical analyses 
the SPSS ver. 17. 
III.       RESULTS 
 After the application of the SVM classifier with an RBF 
kernel, the results obtained are shown in Table II. In this Table 
the three binary schemes selected for classification and the 
corresponding number of voxels per scheme, are shown. 
 
Following the strategy described in the Materials and 
Methods section the statistical t- test has been applied to 
estimate possible significant differences between the mean 
values of the five metabolites in each type of glioma dataset. 
The results of this procedure are presented in Table III.  
 
A graphical representation of Table III is shown in Fig. 4. 
The colored bars clearly present the mean values differences 
of glucose, pyruvate, alanine, lactate and lipids in each type of 
gliomas. 
TABLE II.  BINARY CLASSIFICATION SCEMES 
Binary schemes Voxels / scheme AUROC measured 
GR2 vs GR3 176 vs 57 86 % 
GR3 vs GR4 57 vs 70 98 % 
GR2 vs GR4 176 vs 70 100 % 
TABLE III.  INDEPENDENT SAMPLES T-TEST RESULTS 
Metabolites GR2 vs GR3 GR3 vs GR4 GR2 vs GR4 
Glucose NS HS HS 
Pyruvate S NS S 
Lactate HS HS HS 
Alanine HS HS HS 
Lipids HS HS HS 
HS: p value < 0,001 – S: p value < 0,05 – NS: p value > 0,05 
Figure 4.  The mean peak-area values of the 5 metabolites measured in the 3 
classes provided. 
 
 
 
 
Examining the classification results in Table II we can 
clearly observe that the highest AUROC accuracy values of 
98% and 100% are derived from GR3 vs GR4 and GR2 vs 
GR4 binary schemes, respectively. On the other hand, in GR2 
vs GR3 scheme a smaller AUROC value of 86% is obtained. 
The latter is possibly due to the fact that class GR2 in the 
initial dataset depicts great heterogeneity between the patients. 
More specifically, 90 out of 176 voxels of this class are 
diffuse astrocytoma while the rest 86 voxels are a mixture of 
low grade gliomas (oligodendrogliomas). This has a negative 
impact to the classifier learning process. 
The high accuracy values of the second and third binary 
schemes (GR3 vs GR4 and GR2 vs GR4) can be also justified 
from the statistical analysis results presented in Table III and 
Fig. 4.  As we can observe, the glucose metabolite plays a very 
significant role in the discrimination of intermediate from high 
and low from high grade gliomas. This does not happen, 
however, in the first binary scheme where this metabolite has 
not a significant contribution in the discrimination of low from 
intermediate grade gliomas since its mean values do not differ 
among the two classes. 
The significance of these metabolites is further verified in 
a second stage considering their biological effects as reported 
in other relevant studies. Glucose forms the initial metabolic 
substrate that triggers the glycolysis pathway, as explained in 
the Introduction. In low and intermediate grade tumors, where 
the tumorous cells are proliferating with a slower rate, the 
energy demands remain low. This implies that the glycolysis 
process in not an urgent process at this level. This is not the 
case in high grade tumors, as in GR4. At that stage of the 
disease, the energy needs exceed the predefined limits that 
cause extremely high glycolytic rates i.e. high glucose 
consumption [4].  
Now, when oxygen is present in a tumorous area, the high 
glucose consumption forces the generation of pyruvate in the 
mitochondria and so there is no need for lactate production.  
But when highly hypoxic-necrotic areas exist, like in GR4, 
glucose is converted to lactate (anaerobic glycolysis) which is 
an energy rich molecule. In addition, given some oxygen, 
lactate can also be converted to pyruvate and so enter the 
mitochondria to generate a bucket load of ATP but also lipids, 
as shown in Fig. 1. So lactate with oxygen is a potent 
combination for ATP generation. Furthermore, alanine can be 
produced during hypoxia by transamination to pyruvate from 
another amino acid [8].  
As observed in Fig. 4 pyruvate levels vary in GR2 vs GR3 
and GR2 vs GR4. This is not the case though when cancer 
cells rapidly proliferate upgrading thus from GR3 to GR4. 
This is expected since pyruvate is immediately converted to 
either lactate after the glycolytic process (Warburg effect) 
through the fermentation process or lipids through the 
lipogenesis process. Therefore, lactate lipids and alanine 
metabolic levels increase rapidly as the malignancy increases. 
The highly statistical differences in their mean values also 
prove this tendency. Another important observation in Fig. 4 is 
the rapid increase of both lactate and lipids in GR4 compared 
to their levels in GR3 and GR2. This fact underlines the lack 
of oxygen in this tumorous tissue [13-14].  
Comparing to similar studies [15-16] we can observe that 
high classification rates were achieved in this study too, but in 
contrast to these studies the biological significance of the 
metabolic markers was further evaluated through their energy 
metabolic pathway.  
Based on the above-mentioned observations and the 
classification accuracies obtained using these five metabolites, 
we conclude with high confidence to the fact that these 
metabolites possess a significant role in the discrimination of 
glioma types and grades.  In essence, by examining their 
biochemical profile we can determine the energy flux within 
the cancerous cells, which can be supportive in today’s 
clinical practice.  
IV. CONCLUSIONS 
 The study of bioenergetics in gliomas is a very promising 
field for clinical and biological management of complex brain 
tumors since the energy production and consumption 
processes underline the cancer cells behavior. Glycolysis 
pathways (both aerobic and anaerobic), lactate fermentation, 
citric acid cycle and lipogenesis are crucial tasks for the 
proper function of any cell, since they are responsible for the 
production and consumption of the energy resources. This fact 
motivated us to examine these pathways in order to reveal the 
biochemical profile of several metabolites and furthermore test 
their discriminative power in a real database of glioma 
patients. 
On the other hand, 1H or proton Magnetic Resonance 
Spectroscopy Imaging (1H-MRSI) can provide information on 
the metabolic profile of tissue and is increasingly being used 
as a noninvasive method for classifying brain lesions. Earlier 
MRS studies have shown clear differences between the 1H 
spectra of brain tumors and normal brain tissue [17].  
Taking advantage of the biochemical activities of glucose, 
pyruvate, lactate, alanine and mobile lipids and also their peak 
area levels derived from the analysis of 1H-MRSI spectra, we 
managed to show that these five metabolites are highly 
significant for grade discrimination, as well as for the 
classification of new glioma patients. 
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